Listen

Description

Sixty-five per cent of patients on standard-dose heparin on ECMO had a severe bleed. Eleven per cent had a severe clot. And the heparin is there to prevent the eleven.

This is a journal club on RATE, published in The Lancet in July 2026: the first adequately powered randomised trial of anticoagulation intensity on ECMO. Three hundred and thirty adults on veno-venous or veno-arterial ECMO across seven Dutch intensive care units were randomised to standard-dose unfractionated heparin (APTT 2–2.5 times baseline), low-dose unfractionated heparin (1.5–2 times baseline) or therapeutic subcutaneous low-molecular-weight heparin.

We go through the question, the methods, the non-inferiority margin and what it actually means, and the results: both lower-intensity strategies were non-inferior, with no increase in thrombosis, no extra oxygenator changes, and a consistent but non-significant lean towards less bleeding and fewer deaths.

Then the critique — a composite endpoint dominated by death and bleeding, wide confidence intervals, a narrow definition of thrombosis, unstandardised APTT reagents, two thirds of ECMO patients never enrolled, and the practical problems with subcutaneous low-molecular-weight heparin in shocked patients — and the strengths.

Finally, what it means for us. Our unit already runs heparin at very low doses and reserves full anticoagulation for a specific indication such as pulmonary embolism; ECMO on its own isn't one. RATE draws the same line. And the practical point every resident should take away: blood products go through a peripheral drip, never the central line, because the oxygenator is downstream.

Chapters

Key takeaways

References / further reading

Follow the podcast
Bluesky: @cardiacoutput.bsky.social
X: @CardiacOutputMC

If you've found this useful, a follow or a share genuinely helps other trainees find it — and do get in touch if there's a topic you'd like covered.

This podcast is for medical education for healthcare professionals. It is not clinical advice.